Maternal obesity and metabolic disorders associate with

congenital heart defects in the offspring:

a systematic review

Gitte Hedermann*[1], Paula L Hedley[1], Ida N Thagaard[1,2], Lone Krebs[3,4], Charlotte Kvist Ekelund[4,5], Thorkild IA Sørensen[6,7], Michael Christiansen[1,8]

[1] Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum Institut, Copenhagen, Denmark

[2] Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Slagelse Hospital, Slagelse, Denmark

[3] Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Amager and Hvidovre Hospital, Copenhagen, Denmark

[4] Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

[5] Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

[6] Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark

[7] The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[8] Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

* Corresponding author. E-mail: gihc@ssi.dk (GH)

Abstract

Background

Congenital heart defects (CHDs) are the most common congenital malformations. The aetiology of CHDs is complex.

Large cohort studies and systematic reviews and meta-analyses based on these have reported an association between

higher risk of CHDs in the offspring and individual maternal metabolic disorders such as obesity, diabetes,

hypertension, and preeclampsia, all conditions that can be related to insulin resistance or hyperglycaemia. However,

the clinical reality is that these conditions often occur simultaneously. The aim of this review is, in consequence, both

to evaluate the existing evidence on the association between maternal metabolic disorders, defined as obesity,

diabetes, hypertension, preeclampsia, dyslipidaemia and CHDs in the offspring, as well as the significance of

combinations, such as metabolic syndrome, as risk factors.

Methods

A systematic literature search of papers published between January 1, 1990 and October 6, 2019 was conducted using

PubMed and Embase. Studies were eligible if they were published in English and were case-control or cohort studies.

The exposures of interest were maternal overweight or obesity, hypertension, preeclampsia, diabetes, dyslipidaemia,

and/or metabolic syndrome, and the outcome of interest was CHDs in the offspring. Furthermore, the studies were

included according to a quality assessment score.

Results

Of the 2,076 identified studies, 30 qualified for inclusion. All but one study investigated only the individual metabolic

disorders. Some disorders (obesity, gestational diabetes, and hypertension) increased risk of CHDs marginally whereas

pre-gestational diabetes and early-onset preeclampsia were strongly associated with CHDs, without consistent

differences between CHD subtypes. A single study suggested a possible additive effect of maternal obesity and

gestational diabetes.

Conclusions

Future studies of the role of aberrations of the glucose-insulin homeostasis in the common aetiology and mechanisms

of metabolic disorders, present during pregnancy, and their association, both as single conditions and – particularly –

in combination, with CHDs are needed.

Introduction

Congenital heart defects (CHDs) are structural malformations of the heart and/or the great intrathoracic vessels. They

are the most frequent congenital malformation [1] and prevalence is estimated to be around 8-10 per 1,000 live births

worldwide [1–4]. The most critical and severe defects, the major CHDs, (1-2 per 1,000 live births) have a serious

impact on neonatal mortality and morbidity, and frequently result in neonatal heart failure or circulatory collapse

requiring acute surgery [4]. However, other types of CHDs, like bicuspid aortic valve and transient septal heart defects,

are far more frequent but of limited clinical significance.

The aetiology of CHDs is complex and poorly understood. An identifiable underlying cause (genetic and/or

environmental) is present in 20-30% of CHDs [5]. Thus, 8-10% of CHDs can be attributed to chromosomal aberrations

(e.g., DiGeorge syndrome, Down syndrome, Turner syndrome, etc.) [5,6]; while 5-15% may be the result of single-

nucleotide or pathogenic copy number variants [5,7]. Additionally, viral infections in pregnancy (e.g., rubella), as well

as exposure to certain teratogenic substances (e.g., alcohol or antiepileptic drugs) [8] may cause CHDs if the foetus is

exposed at a critical point in development.

The normal pregnancy is an adaptive interplay between the maternal metabolism and foetal development.

Differentiation of cardiac tissues begins in the third week of gestation, and by week eight, the foetal heart has

undergone major changes, and will resemble the postnatal heart in structure and function [9]. Thus, the maternal-

foetal interaction in the first two months of pregnancy is likely to be the most relevant window in time for a causative

relation between maternal metabolism and CHDs. In first trimester, the foetus does not have the ability to secrete

insulin, which may result in foetal hyperglycaemia in the event of relative maternal insulin resistance [10]. Animal

models have shown that in embryos of chicks and rodents, exogenous glucose may cause a variety of malformations

[11,12]. The significance of foetal hyperglycaemia has not been demonstrated in humans, but increasingly worse

glycaemic control around conception in women with diabetes type 1 (DM1) has recently been reported to be

associated with a progressively increased risk of CHDs in the offspring [13].

Large cohort studies from Scandinavia and North America have reported an association between increased risk of

CHDs and maternal metabolic disorders such as obesity [14,15], diabetes [16–18], hypertension [19,20], and

preeclampsia (PE) [21,22]. All these metabolic disorders can be associated with hyperglycaemia and underlying insulin

resistance, and thereby with the metabolic syndrome (MetS) [23,24]. There is a need to examine the evidence base

for associations between combinations of maternal metabolic disorders, e.g. MetS, and CHDs. Either to complement

existing knowledge or to define important new areas of research.

MetS includes a cluster of metabolic disorders in combination, usually any three of the following: abdominal obesity,

insulin resistance, hypertension, and dyslipidaemia [23,25]. It is commonly reported to be a risk factor for diabetes

type 2 (DM2) and cardiovascular disease in a non-pregnant population. Only a single multi-centre study from

Australia, New Zealand and United Kingdom has assessed MetS in pregnant women and reported an incidence of

12.3% at 15 weeks' gestation [26] using the International Diabetes Federation criteria [25]. It is plausible that obesity,

diabetes, hypertension, PE and dyslipidaemia as individual conditions, or more likely in combination, during pregnancy

are expressions of insulin resistance and MetS [23,24]. Combinations of several maternal metabolic disorders in the

same pregnancy (defined as obesity, diabetes, hypertension, PE, and dyslipidaemia), all related to MetS, are likely to

be associated with higher risk of CHDs in the offspring as compared to women with a single disorder. The evidence

base for an association between CHDs and combinations of metabolic disorders has not been systematically

examined.

The aim of this systematic review is to evaluate the literature of associations between maternal metabolic disorders

(obesity, diabetes, hypertension, PE, dyslipidaemia, or MetS) and particularly combinations thereof and CHDs in the

offspring. The relation with overall occurrence of CHDs as well as CHDs broken down into individual subtypes. Since

these maternal metabolic disorders likely persist over time, they may be relevant for the risk of CHDs in subsequent

pregnancies. Furthermore, we examined the extent to which recent reviews have mentioned the possibility of

combined maternal disorders. On this background, we will point to gaps in current knowledge and make

recommendations for future research possibly paving the way to improved prevention of CHDs.

Materials and methods

Search strategy

Following the Systematic Reviews and Meta-Analyses (PRISMA) checklist (S1 Appendix), a systematic literature search

of papers published between January 1, 1990 and October 6, 2019 was conducted using PubMed and Embase. MetS

was initially described by G.M. Reaven in 1988 as an "insulin resistance syndrome" [27], and the literature search was

limited to publications focussing on its role in CHDs. The search strategy used keywords that combined CHDs and

pregnancies with maternal metabolic disorders (obesity, diabetes, hypertension, PE, dyslipidaemia and/or MetS).

Although DM1 is not a part of the MetS, it was included in the review as a metabolic disorder because the associated

hyperglycaemia is known to be associated with CHDs. More details about the literature search can be found in S1

Table. Subsequently, reference lists from the individual papers were reviewed for additional relevant studies.

Exposures, outcomes and definitions

The exposures of interest were maternal overweight and obesity, diabetes (DM1, DM2 or gestational diabetes

(GDM)), hypertension, PE, dyslipidaemia, and/or MetS during pregnancy. Maternal body mass index (BMI) (weight in

kilograms divided by the square of the height in meters (kg/m^2)) was defined as pre-pregnancy or early-pregnancy BMI

measured in first trimester. The outcome of interest was CHDs defined as structural malformations of the heart

chambers, heart valves, great arteries and septal defects, corresponding to DQ20-26 in the World Health Organization

International Classification of Diseases (ICD-10) or diagnoses referable to these. The CHD diagnoses are described as

"any CHDs" for the whole group of heart defects (only including studies that explicitly listed their definition thereof),

"major CHDs" for a group of the most critical and severe CHD diagnoses or as CHD subtypes in relation to the maternal

disorders. Studies could include both singleton and multiple births.

Eligibility criteria

Two different authors (GH, PLH and/or INT) screened all titles and abstracts individually. Studies were initially eligible

if they met the following criteria: 1. Studies were published in English; 2. Studies were case-control or cohort studies;

3. The exposures of interest were maternal overweight or obesity, hypertension, PE, diabetes, dyslipidaemia, and/or

MetS; and 4. The outcome of interest was CHDs in the offspring.

Quality assessment

One author (GH) conducted the study selection and quality assessment based on a full-text review. Any doubts were

resolved by discussion with at least one co-author. The Newcastle-Ottawa Scale was used to assess the quality of

eligible studies [28]. Using this tool (S2 Table), each study was judged on three categories: 1. selection of cohorts or

cases and controls; 2. comparability of cohorts or cases and controls on the basis of the design or analysis; and 3.

ascertainment of outcome or exposure. Highest quality studies could be awarded nine stars. If a study received seven

or more stars (S3 Table), it was considered of high methodological quality and included in the review [28]. Studies

were excluded if they had less than 15 CHD cases in total. In consequence, some studies will only contain few cases of

each CHD subtype.

Data was extracted to figures without processing results. Results are presented as odds ratios (OR), risk ratios (RR) or

prevalence ratios (PR) with 95% confidence interval (CI). Results are presented adjusted (aOR/aRR/aPR) for pertinent

possible confounding factors, if accessible.

Results

Study identification and selection

The selection of studies is described in Fig 1. In the event of multiple publications using the same data, we included

the study that provided the most comprehensive information. A total of 30 publications were included in the review

(Table 1 and S3 Table). Among these, 15 dealt with maternal overweight or obesity [14,15,19,29–40], nine dealt with

pre-gestational diabetes (PGDM) [16–18,40–45], four dealt with DM1 [13,19,46,47], two dealt with DM2 [19,46],

seven dealt with GDM [16–18,39,40,44,47], four dealt with hypertension [19,20,41,46], three dealt with PE [21,22,48],

and none were about dyslipidaemia or MetS (as a diagnostic category). Except for the combination of PGDM and

GDM, five studies investigated more than one maternal metabolic disorder (but not in combination) [19,39–41,46],

and one study assessed a combination of two conditions (obesity and GDM) and the risk of CHDs [31].

Fig 1. Flow diagram. The process of selection of studies that were included in the review. Literature search included

studies published from January 1, 1990 to October 6, 2019. Abbreviations: CHDs, congenital heart defects; ICD,

International Classification of Disease; NOS, Newcastle-Ottawa Scale

Table 1. Summary table of characteristics of included studies

Characteristics	Range of values
Year of publication	1991-2019
Country of study population	North America (n=15), Europe (n=12), Other countries (n=3)
Study design	Cohort (n=17), Case-control (n=13)
Population size	Cohorts (41 013 - 4 207 898), Case-controls (525 - 1 124 370)
Cases with CHDs	Cohorts (233 - 48 249), Case-controls (35 - 10 625)
Included study population	Only live births (n=15); Live births + stillbirths (n=8); Live births + stillbirths + terminated pregnancies (n=7)
Plurality	Singletons (n=13), All (n=8), Not stated (n=9)
Maternal exposure	Obesity (n=15), PGDM (n=9), DM1 (n=4), DM2 (n=2), GDM (n=7), hypertension (n=4), PE (n=3), obesity+GDM (n=1)

Sources of maternal exposure	Registers (n=18), interviews (n=9), medical records (n=2), questionnaire+medical records (n=1)
Studies of each CHD subtype	Heterotaxia (n=9), UVH (n=6), Conotruncal defects (n=8), Common truncus (n=7), TGA (n=20), ToF (n=20), DORV (n=3), Aortic arch defects (n=1), AVSD (n=17), TAPVR (n=8), LVOT (n=9), HLHS (n=12), CoA (n=14), Aortic stenosis (n=8), RVOT (n=9), Pulmonary valve stenosis (n=8), Ebstein's anomaly (n=5), Septal defects (n=6), ASD (n=21), VSD (n=18)
Newcastle-Ottawa Scale (NOS) score	$7 - 8$

A more comprehensive version of the table is available as S3 Table. Details on NOS score can be seen in S2 Table.

Abbreviations: ASD, atrial septal defects; AVSD, atrioventricular septal defects; CoA, coarctation of the Aorta; DM1,

diabetes type 1; DM2, diabetes type 2; DORV, double outlet right ventricle; GDM, gestational diabetes; HLHS,

hypoplastic left heart syndrome; LVOT, left ventricular outflow tract defects; PE, preeclampsia; PGDM, pre-gestational

diabetes; RVOT, right ventricular outflow tract defects; TAPVR, total anomalous pulmonary venous return; TGA,

transposition of the great arteries; ToF, Tetralogy of Fallot; UVH, univentricular heart; VSD ventricular septal defects.

Study characteristics

The 30 included studies consisted of 17 cohort studies and 13 case-control studies. Characteristics of the 30 studies

are presented in Table 1 and S3 Table. Two examined populations of non-European descent (Taiwan and China)

[39,46]. Half of the studies reported results from livebirths only; eight studies had populations including both singleton

and multiple births; and nine studies did not state whether they included only singleton or multiple births.

Associations between maternal metabolic disorders and CHDs are illustrated in Fig 2 (any CHDs) and S1-S20 Figs (CHD

subtypes). All 30 studies were assessed using the Newcastle-Ottawa Scale and were required to be of high

methodological quality (S2 Table and S3 Table). Study designs were heterogeneous, particularly regarding the

definition and categorization of the maternal metabolic disorders.

Fig 2. Maternal metabolic disorders and risk of any congenital heart defect in the offspring. Any CHDs defined as the

whole group of heart defects (only including studies that explicitly listed their definition thereof). Obesity is defined as

BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as diagnosed before gestational week 34; and PGDM are

defined as DM1 or DM2. All risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤,

obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2; ¥, BMI ≥ 28 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated

hypertension; ‡, estimate only for severe CHDs; @, results from singleton pregnancies. Abbreviations: BMI, body mass

index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia;

PGDM, pre-gestational diabetes; PR, prevalence ratio; RR, risk ratio.

Maternal overweight or obesity and CHDs in the offspring

Several studies have investigated the association between maternal overweight or obesity and any CHDs

[14,15,19,31,33,37,49]. In Fig 2, four out of seven studies found a significant association between maternal obesity

(BMI ≥ 30 kg/m^2) and any CHDs. Three of them reported higher risk estimates for any CHDs with higher maternal BMI:

RR 1.07 (BMI 25-29.9 kg/m^2) and RR 1.60 (BMI ≥ 40 kg/m^2) [14]; aOR 1.15 (BMI 25-29.9 kg/m^2) and aOR 1.34 (BMI ≥ 40

kg/m^2) [15]; and aOR 1.16 (BMI 25-29.9 kg/m^2) and aOR 1.31 (BMI ≥ 35 kg/m^2) [31]. The fourth study only reported an

association between maternal obesity diagnosed as ICD-10 codes and any CHDs, and did not assess the risk in relation

to BMI categories [19]. Three studies found no significant association between any CHDs in the offspring and maternal

overweight or obesity [33,37,49].

Most studies investigated specific CHD subtypes in relation to maternal BMI, these results are presented for maternal

obesity (BMI ≥ 30 kg/m^2) in S1-S20 Figs and summarized in Table 2. Some studies found significant associations

between obesity and 13 CHD subtypes, however, other studies did not find a significant association.

Table 2. Overview of association between congenital heart defect subtypes and maternal exposures.

	Obesity	PGDM	DM1	DM2	GDM	Hypertension	PE (early-onset)	Obesity + GDM
Heterotaxia	2↓	3(**2**)↑	1↑	1(**1**)↑	2↑	1↑ 1↓	2(**1**)↑ 1↓	1↑
UVH	2↑	2(**1**)↑	NA	NA	1↑	1↑ 1↓	1(**1**)↑	1↓
Conotruncal defects	4(**2**)↑ 1↓	3(**2**)↑	1(**1**)↑	1(**1**)↑	1↑	2(**1**)↑	1(**1**)↑	1↑
Common truncus	1↑	3(**2**)↑	NA	NA	1(**1**)↑	2(**1**)↑	1(**1**)↑	NA
TGA	8(**2**)↑ 3↓	6(**3**)↑	NA	NA	2↑	2↓	2↓	1↓
ToF	7(**3**)↑ 4↓	5(**4**)↑	NA	NA	2(**1**)↑	2(**1**)↑	1↑ 1↓	1(**1**)↑
DORV	1↑	1(**1**)↑	NA	NA	NA	NA	1(**1**)↑	NA
Aortic arch defects	1(**1**)↑	NA	NA	NA	NA	NA	NA	NA
AVSD	6(**2**)↑	6(**5**)↑	1(**1**)↑	1(**1**)↑	3(**1**)↑ 1↓	3(**2**)↑	3(**3**)↑	1↑
TAPVR	1↑ 1↓	4(**2**)↑	NA	NA	1(**1**)↑ 1↓	1↓	1(**1**)↑	1↑
LVOT	2(**1**)↑ 2↓	4(**4**)↑	1(**1**)↑	1(**1**)↑	2(**1**)↑	1↑	1↓	1(**1**)↑
HLHS	5(**2**)↑ 1↓	3(**1**)↑	NA	NA	1↑ 1↓	1↑ 1↓	1↑ 1↓	1(**1**)↑
CoA	5↑ 1↓	5(**3**)↑	NA	NA	2(**1**)↑	1(**1**)↑ 1↓	2↑	1↑
Aortic stenosis	2(**1**)↑ 1↓	4(**3**)↑	NA	NA	1(**1**)↑ 1↓	1↑ 1↓	NA	1↑
RVOT	3(**2**)↑ 1↓	4(**3**)↑	1↑	1↑	2(**1**)↑	1(**1**)↑	1(**1**)↑	1(**1**)↑
Pulmonary valve stenosis	4(**2**)↑	3(**2**)↑	NA	NA	2(**1**)↑	1(**1**)↑	NA	1(**1**)↑

Ebstein's anomaly	1↑	1(1)↑	NA	NA	1↑	2↑	1↑	NA
Septal defects	3(1)↑	2(2)↑	NA	NA	1(1)↑	NA	1(1)↑	1(1)↑
VSD	10(3)↑	7(5)↑	1(1)↑	1(1)↑	2(1)↑	3(3)↑	3(3)↑	1↑
ASD	9(6)↑	5(3)↑ 1↓	1(1)↑	1(1)↑	2(1)↑	2(2)↑ 1↓	2(2)↑	1(1)↑

Numbers reflect number of studies examining specific combinations of CHD subtype and exposure. Numbers of significant associations are given in bold and

brackets. Arrows reflect positive (↑) and negative (↓) directions of the associations. The individual studies are detailed in S1-S20 Figs. Abbreviations: ASD, atrial

septal defects; AVSD, atrioventricular septal defects; CoA, coarctation of the Aorta; DM1, diabetes type 1; DM2, diabetes type 2; DORV, double outlet right ventricle;

GDM, gestational diabetes; HLHS, hypoplastic left heart syndrome; LVOT, left ventricular outflow tract defects; PE, preeclampsia; PGDM, pre-gestational diabetes;

RVOT, right ventricular outflow tract defects; TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great arteries; ToF, Tetralogy of Fallot;

UVH, univentricular heart; VSD ventricular septal defects.

Maternal pre-gestational diabetes and CHDs in the offspring

Most studies defined PGDM as either DM1 or DM2 (S3 Table). Only four studies assessed DM1 or DM2 individually [13,19,46,47]. Seven studies found a strong significant association with any CHDs (Fig 2), irrespective of the type of diabetes investigated, PGDM [16–18,44], DM1 [13,19,46], or DM2 [19,46].

Two studies presented associations between PGDM and major CHDs, but they defined major CHDs differently: Leirgul et al. found an association between PGDM and major CHDs (aRR 3.34, CI 2.48-4.49) [18], and Chou et al. found an association between DM2 and major CHDs (aOR 2.80, CI 2.04-3.85), but did not find a significant association between DM1 and major CHDs (aOR 0.73, 0.10–5.32) [46].

Several studies have investigated the relationship between PGDM, DM1 or DM2 and specific CHD diagnoses [16–19,40–45,47] and in many cases found a strong significant association (S1-S20 Figs and Table 2).

Maternal gestational diabetes and CHDs in the offspring

Five studies reported an association between GDM and any CHDs [16–18,39,44], but only the results from four of them are shown in Fig 2. The last study by Øyen et al. found an association between any CHDs and GDM diagnosed in the third trimester (aRR 1.36; CI 1.07-1.69), but did not find a significant association between any CHDs and GDM diagnosed in the second trimester [16]. Five studies reported a weak association between GDM and some subtypes of CHDs (S1-S20 Figs and Table 2).

Maternal chronic hypertension and CHDs in the offspring

Two large cohort studies from Canada and Taiwan reported a significant association between maternal pre-existing chronic hypertension and any CHDs (Fig 2) [19,46]. Two studies assessed the association between subtypes of CHDs and chronic hypertension [19,41], (S1-S20 Figs), but associations were inconsistent. None of the three studies mentioned reported on potential antihypertensive drug use by the mothers. An American case-control study with

224   10,625 cases with CHDs found a significant association between untreated hypertension and any CHDs (Fig 2) as well

225   as for five subtypes of CHDs (S1-S20 Figs and Table 2) [20].

227   Maternal preeclampsia or gestational hypertension and CHDs in the

228   offspring

Three studies investigated associations between PE and any CHDs or major CHDs. Although the definition of PE varied

among the studies, all studies defined early-onset PE as diagnosed before gestational week 34, and the association

with any CHDs can be seen in Fig 2. Pregnancies with PE were associated with any CHDs (PR 1.57, CI 1.48-1.67) [22],

and early-onset PE was associated with major CHDs (aRR 2.7, CI 1.3-5.6 [48], and aPR 3.64, CI 2.17-6.10 [22]), all

compared to normotensive pregnancies.

Weaker associations, between PE and any CHDs, were reported when PE was diagnosed later in pregnancy: PE with

delivery at 34 to 36 weeks (OR 2.82, CI 2.38-3.34) [21]; PE at term (OR 1.16, CI 1.06-1.27) [21]; and late-onset PE (> 34

weeks' gestation) (aPR 1.14, CI 1.06-1.23) [22]. Furthermore, Boyd et al. did not find an association between

gestational hypertension and any CHDs [21]. The studies also assessed subtypes of CHDs and their association with

early-onset PE, which are illustrated in S1-S20 Figs and summarized in Table 2, especially atrioventricular septal

defects (S9 Fig) and atrial septal defects (S19 Fig) were strongly associated with early-onset PE.

241   Risk of CHDs in the offspring in subsequent pregnancies

Two studies assessed PE and CHDs, and potential risks of both in subsequent pregnancies [21,48]. While, Brodwall et

al. did not find an association between PE and CHDs across pregnancies [48], Boyd et al. reported a much higher risk

of having a child with CHDs in subsequent pregnancies after a pregnancy with PE and delivery before 34 weeks'

gestation (OR 7.91, CI 6.06-10.3). Boyd et al. also found an association between a previous pregnancy with a child with

CHDs and increased risk of PE with delivery before 34 weeks' gestation in subsequent pregnancies (OR 2.37; CI 1.68-

3.34) [21]. Studies on the other maternal metabolic disorders did not comprise an analysis of risks in subsequent

pregnancies.

Combination of maternal obesity and gestational diabetes and CHDs in the offspring

252   Only one study comprised an assessment of the risk associated with pregnancies affected by two maternal metabolic

253   conditions. Gilboa et al. reported a possible additive effect of the combination of maternal obesity (BMI ≥ 30 kg/m^2)

254   and GDM and the risk of any CHDs compared to only obesity (aOR 1.82 vs. 1.31) [31]. The relation between the

255   combination of maternal obesity and GDM and subtypes of CHDs are reported in S1-S20 Figs and summarized in Table

256   2 showing a significant association for six subtypes of CHDs.

Trends in associations of specific CHD subtypes

259   As shown in Table 2, there are no clear differences in the direction of associations between CHD subtypes and

260   individual maternal metabolic disorders. Of note is that none of the studies, suggesting reduced risk of CHD was

261   statistically significant.

Recent reviews

264   Systematic reviews and meta-analyses further documented the associations for some of the individual maternal

265   metabolic disorders: obesity [50–52], diabetes [17,53,54], and hypertension [55]. However, only a single review

266   mentioned combinations of GDM and obesity, citing only two studies [56]. No reviews sought to estimate the effect of

267   simultaneous presence of several metabolic disorders.

Discussion

Main findings

The associations between any CHDs and maternal metabolic disorders fall in three groups: A. chronic hypertension, GDM, and obesity with OR/RR/PR of 1.2-1.9; B. PGDM with OR/RR/PR around 3-4; and C. early-onset PE with OR/RR/PR of 5-7. Thus, for the most prevalent maternal conditions, the associated risks of CHDs are only marginally elevated. Although maternal obesity is associated with higher risk of GDM, DM2, hypertension, PE, and dyslipidaemia [57], no studies assessing the association between CHDs in the offspring and the combination of all maternal metabolic disorders were identified, and only one study dealt with the combination of two maternal metabolic conditions (obesity and GDM) as risk factor for CHDs in the offspring [31]. All other studies investigated the individual metabolic disorders and their association with CHDs, and there were no eligible studies on dyslipidaemia. Overall, those studies found a significant association between any CHDs and obesity, PGDM, GDM, hypertension, or early-onset PE, respectively (Fig 2). Contradictory evidence of associations with subtypes of CHDs were noted for most maternal conditions, with the exception of early-onset PE, which was strongly associated with both atrioventricular septal defects (S9 Fig) and atrial septal defects (S19 Fig); and PGDM which was strongly associated with most subtypes (S1-S20 Figs).

Early-onset PE was strongly associated with a higher risk of having a child with CHD in subsequent pregnancies, studies on the other maternal metabolic disorders did not approach risks in subsequent pregnancies.

There was no discernible pattern of associations between CHD subtypes and metabolic disorders (Table 2). However, the number of studies for many of the combinations is very small.

Aetiological considerations and possible prevention of CHDs

Relation between maternal metabolic disorders and foetal heart development

There is a clear pathophysiological connection between maternal insulin resistance and foetal CHDs, with glucose-

mediated mechanisms of CHD involving multiple developmental pathways [58]: comprise left-right patterning [59],

alterations in neural crest cells migration and formation [60,61], increased apoptosis [62,63] as well as changes in

nitric oxide signalling [64], and impaired autophagy [65]. All these mechanisms may cause or modify the development

of CHDs. The investigated maternal metabolic disorders (obesity, diabetes, hypertension, preeclampsia, dyslipidaemia,

and MetS) are all linked to insulin resistance and/or hyperglycaemia [24,66]. The finding of the same association for

these conditions as for DM1 [16] justifies a particular focus on the role of aberrations in the glucose-insulin

homeostasis. Obesity, DM1, DM2, chronic hypertension, and dyslipidaemia are present prior to conception and

therefore affect maternal metabolism and foetal development during the essential first two months of pregnancy.

However, PE and GDM are per definition not diagnosed before mid-pregnancy [67,68], but it is likely that subclinical

metabolic alterations emerge at a much earlier stage. It can be challenging to distinguish GDM from PGDM since most

women are not screened for diabetes before pregnancy, and up to 50% of women diagnosed with GDM develop DM2

within five years after giving birth [69]. So it is plausible that many women with GDM might already be insulin

resistant without it being detectable in first trimester. This is particularly challenging because fasting and postprandial

glucose concentrations are normally lower in the early part of pregnancy (e.g., first trimester and first half of second

trimester) than in normal, non–pregnant women [68]. Insulin resistance is more pronounced early in pregnancies with

PE compared to pregnancies without PE [24,70]. In first trimester pregnancies that later develop PE are characterised

by changes in IGF-axis markers, e.g. PAPP-A, and ProMBP [71,72], placental proteins [73], and adipokines, e.g. leptin

and adiponectin [74,75], indicating that the clinical presentation of PE is preceded by a foeto-maternal dyscrine

condition. The fact that the nutritional status of the foetus influences the risk of cardiovascular disease in adulthood

(Barker Hypothesis) [76] - also indicates that placental function may play a role in the aetiology of foetal

malformations. There is a need to identify particular pathways where perturbations, especially in the glucose-insulin

axis, cause specific malformations, but such studies will have to be large as some of the malformations are fairly rare

and the molecular aetiology likely heterogeneous.

Possible teratogenic effect of medication

Women with chronic hypertension or DM1 will most likely be undergoing medical treatment as well as some women

with DM2 will be treated with antidiabetic drugs. Some of these drugs might have a teratogenic effect and by not

taking them into considerations in the studies, they could influence the estimates of association. It is thus important

to distinguish between the effects of the drugs and the conditions proper. Insulin is not believed to be teratogenic

[77], suggesting that the focus should be on the insulin resistance and the glucose levels. Observational studies

suggest that exposure to either metformin or beta-blockers during pregnancy may actually increase the risk of certain

types of CHDs in the foetus [20,78]. A meta-analysis by Ramakrishnan et al. observed an association between

untreated hypertension and CHDs, which suggests that the association between hypertension and CHDs is not simply

due to teratogenic effects of medication alone, but the effect was larger for treated hypertension [55]. Thus,

antihypertensive medications may lead to an additional increase in risk, but it might also just indicate a more severe

disease in the mother.

Prevention of CHDs in the offspring

It is very well-established that maternal obesity is associated with marginally increased risk of CHDs, and two meta-

analyses reported a dose-response effect on risk of CHDs with increasing BMI [52,79]. But an increase of 20-40% of a

very small risk in general may not be clinically significant. Particularly as it has not yet been shown that weight

reduction normalizes the risk and a study showing such an effect would be complicated and difficult to perform.

Future studies investigating the prevalence of CHDs in obese pregnant women could compare women who had

undergone bariatric surgery with a control group as well as risk in pregnancies before and after the surgery as it has

been done in studies on birth weight and obesity in childhood [80,81]. The Swedish cohort study of 1.2 million

pregnant women with DM1 showed that poor glycaemic control around conception was associated with a

progressively higher risk of CHDs in the offspring [13]. PGDM and early-onset PE have a strong association with CHDs,

however, the clinical significance of preventive measures has not been established.

Heterogeneity in studies

Comparison of results from different studies in this review was hampered by heterogeneity. This is due to several

factors: 1. Case-control studies provide estimates of risk that may be less valid and reliable than prospective,

population-based cohort studies for estimating occurrence of CHDs– i.e., for some subtypes of CHDs, the cohort

studies find a significant association while the results from the case-control studies are insignificant. 2. The studies

assessing maternal obesity and CHDs often excluded pregnancies with PGDM, whereas others did not and are

therefore difficult to compare; studies on obesity usually also divided maternal BMI into categories that distinguished

them from a direct comparison with another study. 3. Diagnostic criteria for PGDM and GDM were not always

explained. 4. Not all studies include stillbirths and terminated pregnancies, which could skew the results, i.e., the risk

of CHDs in live born offspring of women with obesity relative to women without obesity might be overestimated,

since it is well-known that congenital malformations are more difficult to detect by prenatal ultrasound in these

women and they are therefore not necessarily given the possibility to terminate the pregnancy in case of a severe

malformation [82]. 5. Studies on both singleton and multiple births without distinguishing between them may add to

the heterogeneity because the risk of CHDs is higher in multiple birth [83].

We presented adjusted risks and compared them although the studies did not all adjust for the same confounders.

Many studies adjust for maternal age, parity and year of birth, while others also adjust for race/ethnicity, education,

smoking, marital status etc. Even though not always available, we could have presented crude risks, however, we

believe that the adjusted risks represent the best possible estimate since results otherwise would have been known to

be biased.

Significance of genetic aetiology

The aetiology of CHD is complex and the important breakthroughs in next generation sequencing of whole genomes

as well as implementation of chromosomal micro arrays have as of now led to the identification of a strong genetic

component in 15-20% of CHD cases [5]. The genetic aetiology ranges from chromosomal disorders over micro-

deletions to copy number variants and single-gene disorders. Many of the genetic causes of CHDs are characterized by

extensive phenotypic variability and a broad spectrum of comorbidities [5]. Thus, some cases of e.g. Williams

syndrome [84] as well as Bardet-Biedl syndrome [85] exhibit malformations in combinations with obesity, DM2, and

hypertension. In cases where the mother carries genetic variants that cause or pre-dispose to such conditions, the

association between CHDs and maternal metabolic disorders might be one of common aetiology (horizontal

pleiotropy) rather than one of a causal relation between maternal conditions and the development of CHDs (vertical

pleiotropy). With further advances in genetic characterization of CHDs, one might see a more detailed understanding

of the extent of comorbidities in CHD-associated genetic disorders. This phenomenon might bias the association

analysis.

Strengths and limitations

The strength of this review is that we have selected only high-quality, original research studies from a systematic

literature search. However, we have limited our selection of studies to those published in English and from 1990 and

after, which may have excluded a number of high-quality studies, which were published in another language or before

1990. However, the screening of the references of the articles included did not reveal relevant studies published

before 1990. Furthermore, our review did not include meta-analyses as prescribed by PRISMA since we found the data

too heterogeneous to summarize in a meta-analysis. Finally, it should be remembered that some CHD subtypes are

very rare, resulting in very broad confidence intervals in association analyses.

Perspectives

The global birth prevalence of CHDs has increased by 10% every five years between 1970 and 2017, which probably is

due to increased detection of milder lesions [2]. The incidence of MetS often parallels the incidence of obesity, which

has nearly tripled worldwide since 1975 [86], and Centers for Disease Control and Prevention estimated that 40% of

women aged 20-39 years old in the United States had a BMI $\geq$ 30 kg/m^2 in 2017-2018 [87]. Maternal obesity and

dyslipidaemia increases the risk of developing both PE and GDM [88,89], GDM closely associated with risk of DM2, PE

increases the risk of future chronic hypertension [90], and studies indicate that women with PE have increased risk of

insulin resistance later in life [91]. So, the maternal metabolic disorders might be related to later MetS (except for

DM1), and all components are associated with CHDs in offspring – either individually or with an additive effect. Our

analysis shows that there is a remarkable lack of knowledge on several aspects of the link between maternal

metabolic disorders and CHDs in the offspring. Large population-based studies are needed to identify possible

synergistic effects. Indeed, the combination may have a greater impact than each individual factor and result in

amplified risk of CHDs – also taking into consideration at what time the maternal metabolic disorder develops in

relationship to the development of the foetal heart. Furthermore, such studies should be ethnically inclusive, and also

include women of different socio-economic status. There is also a need for more detailed studies of the molecular

mechanisms of CHDs, especially regarding the possibly common underlying pathophysiological mechanisms, insulin

resistance and glucose-insulin homeostasis in particular, and their genomic basis. A combination of such studies in

carefully investigated cohorts and the use of electronic health records in a population-wide biobank setting could

bring relevant knowledge on mechanisms that might pave the way to preventive approaches to CHDs. Furthermore, it

is important to examine whether a modification of a pre-existing condition influences risks for CHDs.

Conclusion

CHDs are the most common malformations and a major cause of morbidity and mortality in childhood. Although the

aetiology is complex, it is important to identify risk factors in order to pave the way for targeted prevention of CHDs.

Our review shows that there is a well-established association, albeit to a varying extent, between individual maternal

metabolic disorders such as obesity, diabetes, hypertension, and PE with increased risk of CHDs in the child. However,

the evidence base for association between combinations of maternal metabolic disorders and CHDs was found to be

very small. Since occurrence of MetS is rapidly increasing, there is a need for such studies. Secondly, there is a need

for large studies based on genetically characterized CHD cases, where the association with MetS could be an

expression of comorbidity involving both CHDs and maternal metabolic disorders implying aberrations of the glucose-

insulin homeostasis. Thirdly, there is a need for studies covering populations other than those of European and Asian

descent, particularly as the prevalence of MetS and its different manifestations vary widely around the globe. Such

studies may result in the identification of subgroups of women, in whom MetS might be of particularly importance as

a risk factor. Finally, it is important to examine whether preventive actions against pre-pregnancy maternal metabolic

disorders influences the risk of CHDs.

Acknowledgements

421   Thank you to the researchers who readily provided supplementary information. This research has been conducted

422   using the Danish National Biobank resource supported by the Novo Nordisk Foundation.

423   An earlier version of the article is available at a preprint server, MedRxiv (DOI:

424   https://doi.org/10.1101/2020.06.25.20140186).

Abbreviations

427   CHDs, congenital heart defects; MetS, metabolic syndrome; PE, preeclampsia; BMI, body mass index; GDM,

428   gestational diabetes; DM2, diabetes type 2; DM1, diabetes type 1; ICD-10, International Classification of Diseases, 10th

429   revision; OR, odds ratio; RR, risk ratio; PR, prevalence ratio; CI, 95% confidence interval; PGDM, pre-gestational

430   diabetes.

References

1.   Dolk H, Loane M, Garne E, European Surveillance of Congenital Anomalies (EUROCAT) Working Group.

Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation. 2011;123:

841–849. doi:10.1161/CIRCULATIONAHA.110.958405

2.   Liu Y, Chen S, Zühlke L, Black GC, Choy M, Li N, et al. Global birth prevalence of congenital heart defects 1970–

2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019;48: 455–463.

doi:10.1093/ije/dyz009

3.   van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJM, et al. Birth Prevalence of

Congenital Heart Disease Worldwide. J Am Coll Cardiol. 2011;58: 2241–2247. doi:10.1016/j.jacc.2011.08.025

4.   Lytzen R, Vejlstrup N, Bjerre J, Petersen OB, Leenskjold S, Dodd JK, et al. Live-Born Major Congenital Heart

Disease in Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013. JAMA

Cardiol. 2018;3: 829–837. doi:10.1001/jamacardio.2018.2009

5.   Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, et al. Genetic Basis for Congenital Heart

Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation. 2018;138: e653–

e711. doi:10.1161/CIR.0000000000000606

6.   van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJM. The changing epidemiology of

congenital heart disease. Nat Rev Cardiol. 2011;8: 50–60. doi:10.1038/nrcardio.2010.166

7.   Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare inherited and de novo variants in

2,871 congenital heart disease probands. Nat Genet. 2017;49: 1593–1601. doi:10.1038/ng.3970

8.   Hoffman JIE. Epidemiology of congenital heart disease: etiology, pathogenesis, and incidence. In: Yagel S,

Silverman NH, Gembruch U, editors. Fetal Cardiology: Embryology, Genetics, Physiology, Echocardiographic

Evaluation, Diagnosis and Perinatal Management of Cardiac Diseases. 2nd ed. Taylor & Francis; 2009. pp. 101-

110.

9.   Wenink ACG. Cardiovascular development. In: Yagel S, Silverman NH, Gembruch U, eds. Fetal Cardiology:

Embryology, Genetics, Physiology, Echocardiographic Evaluation, Diagnosis and Perinatal Management of

Cardiac Diseases. 2nd ed. Taylor & Francis; 2009. pp. 1-8.

10.   Rorsman P, Arkhammar P, Bokvist K, Hellerström C, Nilsson T, Welsh M, et al. Failure of glucose to elicit a

normal secretory response in fetal pancreatic beta cells results from glucose insensitivity of the ATP-regulated

K+ channels. Proc Natl Acad Sci U S A. 1989;86: 4505–4509. doi:10.1073/pnas.86.12.4505

11.   Hughes AF, Freeman RB, Fadem T. The teratogenic effects of sugars on the chick embryo. J Embryol Exp

Morphol. 1974;32: 661–674.

12.   Garnham EA, Beck F, Clarke CA, Stanisstreet M. Effects of glucose on rat embryos in culture. Diabetologia.

1983;25: 291–295. doi:10.1007/BF00279946

13.   Ludvigsson JF, Neovius M, Söderling J, Gudbjörnsdottir S, Svensson A-M, Franzén S, et al. Periconception

glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study

in Sweden. BMJ. 2018;362: k2638. doi:10.1136/bmj.k2638

14.   Persson M, Razaz N, Edstedt Bonamy A-K, Villamor E, Cnattingius S. Maternal Overweight and Obesity and Risk

of Congenital Heart Defects. J Am Coll Cardiol. 2019;73: 44–53. doi:10.1016/j.jacc.2018.10.050

15.   Brite J, Laughon SK, Troendle J, Mills J. Maternal overweight and obesity and risk of congenital heart defects in

offspring. Int J Obes 2005. 2014;38: 878–882. doi:10.1038/ijo.2013.244

16.   Øyen N, Diaz LJ, Leirgul E, Boyd HA, Priest J, Mathiesen ER, et al. Prepregnancy Diabetes and Offspring Risk of

Congenital Heart Disease: A Nationwide Cohort Study. Circulation. 2016;133: 2243–2253.

doi:10.1161/CIRCULATIONAHA.115.017465

17.   Hoang TT, Marengo LK, Mitchell LE, Canfield MA, Agopian AJ. Original Findings and Updated Meta-Analysis for

the Association Between Maternal Diabetes and Risk for Congenital Heart Disease Phenotypes. Am J Epidemiol.

2017;186: 118–128. doi:10.1093/aje/kwx033

18.   Leirgul E, Brodwall K, Greve G, Vollset SE, Holmstrøm H, Tell GS, et al. Maternal Diabetes, Birth Weight, and

480   Neonatal Risk of Congenital Heart Defects in Norway, 1994-2009. Obstet Gynecol. 2016;128: 1116–1125.

481   doi:10.1097/AOG.0000000000001694

482   19.   Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, et al. Association between maternal chronic

483   conditions and congenital heart defects: a population-based cohort study. Circulation. 2013;128: 583–589.

484   doi:10.1161/CIRCULATIONAHA.112.001054

485   20.   Fisher SC, Van Zutphen AR, Werler MM, Lin AE, Romitti PA, Druschel CM, et al. Maternal Antihypertensive

486   Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention

487   Study. Hypertens Dallas Tex 1979. 2017;69: 798–805. doi:10.1161/HYPERTENSIONAHA.116.08773

488   21.   Boyd HA, Basit S, Behrens I, Leirgul E, Bundgaard H, Wohlfahrt J, et al. Association Between Fetal Congenital

489   Heart Defects and Maternal Risk of Hypertensive Disorders of Pregnancy in the Same Pregnancy and Across

490   Pregnancies. Circulation. 2017;136: 39–48. doi:10.1161/CIRCULATIONAHA.116.024600

491   22.   Auger N, Fraser WD, Healy-Profitós J, Arbour L. Association Between Preeclampsia and Congenital Heart

492   Defects. JAMA. 2015;314: 1588–1598. doi:10.1001/jama.2015.12505

493   23.   Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr

494   Rev. 2008;29: 777–822. doi:10.1210/er.2008-0024

495   24.   Jeyabalan A, Hubel CA, Roberts JM. Metabolic Syndrome and Preeclampsia. In: Taylor RN, Roberts JM,

496   Cunningham FG, Lindheimer MD, eds. Chesley's Hypertensive Disorders in Pregnancy. 4th ed. Academic Press;

497   2015. pp. 133-160.

498   25.   O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.

499   Obes Rev Off J Int Assoc Study Obes. 2015;16: 1–12. doi:10.1111/obr.12229

500   26.   Grieger JA, Bianco-Miotto T, Grzeskowiak LE, Leemaqz SY, Poston L, McCowan LM, et al. Metabolic syndrome in

501   pregnancy and risk for adverse pregnancy outcomes: A prospective cohort of nulliparous women. PLoS Med.

502   2018;15: e1002710. doi:10.1371/journal.pmed.1002710

503   27.   Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37: 1595–1607.

504   doi:10.2337/diab.37.12.1595

505   28.   Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for

506   assessing the quality of nonrandomised studies in meta-analyses. Available from:

507   http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

508   29.   Block SR, Watkins SM, Salemi JL, Rutkowski R, Tanner JP, Correia JA, et al. Maternal pre-pregnancy body mass

509   index and risk of selected birth defects: evidence of a dose-response relationship. Paediatr Perinat Epidemiol.

510   2013;27: 521–531. doi:10.1111/ppe.12084

511   30.   Blomberg MI, Källén B. Maternal obesity and morbid obesity: the risk for birth defects in the offspring. Birt

512   Defects Res A Clin Mol Teratol. 2010;88: 35–40. doi:10.1002/bdra.20620

513   31.   Gilboa SM, Correa A, Botto LD, Rasmussen SA, Waller DK, Hobbs CA, et al. Association between prepregnancy

514   body mass index and congenital heart defects. Am J Obstet Gynecol. 2010;202: 51.e1-51.e10.

515   doi:10.1016/j.ajog.2009.08.005

516   32.   Mills JL, Troendle J, Conley MR, Carter T, Druschel CM. Maternal obesity and congenital heart defects: a

517   population-based study. Am J Clin Nutr. 2010;91: 1543–1549. doi:10.3945/ajcn.2009.28865

518   33.   Rankin J, Tennant PWG, Stothard KJ, Bythell M, Summerbell CD, Bell R. Maternal body mass index and

519   congenital anomaly risk: a cohort study. Int J Obes 2005. 2010;34: 1371–1380. doi:10.1038/ijo.2010.66

520   34.   Shaw GM, Carmichael SL. Prepregnant obesity and risks of selected birth defects in offspring. Epidemiol Camb

521   Mass. 2008;19: 616–620. doi:10.1097/EDE.0b013e3181761fa3

522   35.   Cedergren MI, Källén BAJ. Maternal obesity and infant heart defects. Obes Res. 2003;11: 1065–1071.

523   doi:10.1038/oby.2003.146

524   36.   Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal Obesity and Risk for Birth Defects.

525   Pediatrics. 2003;111: 1152–1158.

526   37.   Watkins ML, Botto LD. Maternal prepregnancy weight and congenital heart defects in offspring. Epidemiol Camb
527   Mass. 2001;12: 439–446.

528   38.   Shaw GM, Todoroff K, Schaffer DM, Selvin S. Maternal height and prepregnancy body mass index as risk factors
529   for selected congenital anomalies. Paediatr Perinat Epidemiol. 2000;14: 234–239. doi:10.1046/j.1365-
530   3016.2000.00274.x

531   39.   Liu X, Liu G, Wang P, Huang Y, Liu E, Li D, et al. Prevalence of congenital heart disease and its related risk
532   indicators among 90,796 Chinese infants aged less than 6 months in Tianjin. Int J Epidemiol. 2015;44: 884–893.
533   doi:10.1093/ije/dyv107

534   40.   Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive epidemiology of non-syndromic
535   complete atrioventricular canal defects. Paediatr Perinat Epidemiol. 2012;26: 515–524. doi:10.1111/ppe.12006

536   41.   Vereczkey A, Gerencsér B, Czeizel AE, Szabó I. Association of certain chronic maternal diseases with the risk of
537   specific congenital heart defects: a population-based study. Eur J Obstet Gynecol Reprod Biol. 2014;182: 1–6.
538   doi:10.1016/j.ejogrb.2014.08.022

539   42.   Kovalenko AA, Anda EE, Odland JØ, Nieboer E, Brenn T, Krettek A. Risk Factors for Ventricular Septal Defects in
540   Murmansk County, Russia: A Registry-Based Study. Int J Environ Res Public Health. 2018;15: 1320.
541   doi:10.3390/ijerph15071320

542   43.   Vinceti M, Malagoli C, Rothman KJ, Rodolfi R, Astolfi G, Calzolari E, et al. Risk of birth defects associated with
543   maternal pregestational diabetes. Eur J Epidemiol. 2014;29: 411–418. doi:10.1007/s10654-014-9913-4

544   44.   Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, et al. Diabetes mellitus and birth defects. Am J
545   Obstet Gynecol. 2008;199: 237.e1–9. doi:10.1016/j.ajog.2008.06.028

546   45.   Erickson JD. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. Teratology.
547   1991;43: 41–51. doi:10.1002/tera.1420430106

548   46.   Chou H-H, Chiou M-J, Liang F-W, Chen L-H, Lu T-H, Li C-Y. Association of maternal chronic disease with risk of

549   congenital heart disease in offspring. CMAJ Can Med Assoc J J Assoc Medicale Can. 2016;188: E438–E446.

550   doi:10.1503/cmaj.160061

551   47.   Sharpe PB, Chan A, Haan EA, Hiller JE. Maternal diabetes and congenital anomalies in South Australia 1986-

552   2000: a population-based cohort study. Birt Defects Res A Clin Mol Teratol. 2005;73: 605–611.

553   doi:10.1002/bdra.20172

554   48.   Brodwall K, Leirgul E, Greve G, Vollset SE, Holmstrøm H, Tell GS, et al. Possible Common Aetiology behind

555   Maternal Preeclampsia and Congenital Heart Defects in the Child: a Cardiovascular Diseases in Norway Project

556   Study. Paediatr Perinat Epidemiol. 2016;30: 76–85. doi:10.1111/ppe.12252

557   49.   Liu S, Rouleau J, León JA, Sauve R, Joseph KS, Ray JG. Impact of pre-pregnancy diabetes mellitus on congenital

558   anomalies, Canada, 2002-2012. Health Promot Chronic Dis Prev Can Res Policy Pract. 2015;35: 79–84.

559   50.   Cai G, Sun X, Zhang L, Hong Q. Association between maternal body mass index and congenital heart defects in

560   offspring: a systematic review. Am J Obstet Gynecol. 2014;211: 91–117. doi:10.1016/j.ajog.2014.03.028

561   51.   Zhu Y, Chen Y, Feng Y, Yu D, Mo X. Association between maternal body mass index and congenital heart defects

562   in infants: A meta-analysis. Congenit Heart Dis. 2018;13: 271–281. doi:10.1111/chd.12567

563   52.   Zheng Z, Yang T, Chen L, Wang L, Zhang S, Wang T, et al. Increased maternal Body Mass Index is associated with

564   congenital heart defects: An updated meta-analysis of observational studies. Int J Cardiol. 2018;273: 112–120.

565   doi:10.1016/j.ijcard.2018.09.116

566   53.   Simeone RM, Devine OJ, Marcinkevage JA, Gilboa SM, Razzaghi H, Bardenheier BH, et al. Diabetes and

567   congenital heart defects: a systematic review, meta-analysis, and modeling project. Am J Prev Med. 2015;48:

568   195–204. doi:10.1016/j.amepre.2014.09.002

569   54.   Chen L, Yang T, Chen L, Wang L, Wang T, Zhao L, et al. Risk of congenital heart defects in offspring exposed to

570   maternal diabetes mellitus: an updated systematic review and meta-analysis. Arch Gynecol Obstet. 2019;300:

571   1491-1506. doi:10.1007/s00404-019-05376-6

55.   Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of

Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. Pediatr Cardiol. 2015;36: 1442–

1451. doi:10.1007/s00246-015-1182-9

56.   Parnell AS, Correa A, Reece EA. Pre-pregnancy Obesity as a Modifier of Gestational Diabetes and Birth Defects

Associations: A Systematic Review. Matern Child Health J. 2017;21: 1105–1120. doi:10.1007/s10995-016-2209-4

57.   Denison FC, Aedla NR, Keag O, Hor K, Reynolds RM, Milne A, et al. Care of Women with Obesity in Pregnancy:

Green-top Guideline No. 72. BJOG Int J Obstet Gynaecol. 2019;126: e62–e106. doi:10.1111/1471-0528.15386

58.   Helle E, Priest JR. Maternal Obesity and Diabetes Mellitus as Risk Factors for Congenital Heart Disease in the

Offspring. J Am Heart Assoc. 2020;9: e011541. doi:10.1161/JAHA.119.011541

59.   Basu M, Zhu J-Y, LaHaye S, Majumdar U, Jiao K, Han Z, et al. Epigenetic mechanisms underlying maternal

diabetes-associated risk of congenital heart disease. JCI Insight. 2017;2: e95085. doi:10.1172/jci.insight.95085

60.   Suzuki N, Svensson K, Eriksson UJ. High glucose concentration inhibits migration of rat cranial neural crest cells

in vitro. Diabetologia. 1996;39: 401–411. doi:10.1007/BF00400671

61.   Wang X-Y, Li S, Wang G, Ma Z-L, Chuai M, Cao L, et al. High glucose environment inhibits cranial neural crest

survival by activating excessive autophagy in the chick embryo. Sci Rep. 2015;5: 18321. doi:10.1038/srep18321

62.   Kumar SD, Vijaya M, Samy RP, Dheen ST, Ren M, Watt F, et al. Zinc supplementation prevents cardiomyocyte

apoptosis and congenital heart defects in embryos of diabetic mice. Free Radic Biol Med. 2012;53: 1595–1606.

doi:10.1016/j.freeradbiomed.2012.07.008

63.   Wang F, Fisher SA, Zhong J, Wu Y, Yang P. Superoxide Dismutase 1 In Vivo Ameliorates Maternal Diabetes

Mellitus-Induced Apoptosis and Heart Defects Through Restoration of Impaired Wnt Signaling. Circ Cardiovasc

Genet. 2015;8: 665–676. doi:10.1161/CIRCGENETICS.115.001138

64.   Engineer A, Saiyin T, Lu X, Kucey AS, Urquhart BL, Drysdale TA, et al. Sapropterin Treatment Prevents Congenital

594   Heart Defects Induced by Pregestational Diabetes Mellitus in Mice. J Am Heart Assoc. 2018;7: e009624.

595   doi:10.1161/JAHA.118.009624

596   65.   Wang G, Huang W, Cui S, Li S, Wang X, Li Y, et al. Autophagy is involved in high glucose-induced heart tube

597   malformation. Cell Cycle Georget Tex. 2015;14: 772–783. doi:10.1080/15384101.2014.1000170

598   66.   Reaven GM. Insulin resistance: from bit player to centre stage. CMAJ Can Med Assoc J J Assoc Medicale Can.

599   2011;183: 536–537. doi:10.1503/cmaj.101430

600   67.   Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet Lond Engl.

601   2016;387: 999–1011. doi:10.1016/S0140-6736(15)00070-7

602   68.   WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Available from:

603   https://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/

604   69.   National Institute for Health and Care Excellence. 2018 Surveillance of Diabetes in Pregnancy: Management

605   from Preconception to the Postnatal Period (NICE Guideline NG3). 2015. Available from:

606   https://www.nice.org.uk/guidance/ng3

607   70.   von Versen-Hoeynck FM, Powers RW. Maternal-fetal metabolism in normal pregnancy and preeclampsia. Front

608   Biosci J Virtual Libr. 2007;12: 2457–2470. doi:10.2741/2247

609   71.   Pihl K, Larsen T, Krebs L, Christiansen M. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in

610   prediction of small-for-gestational-age fetuses. Prenat Diagn. 2008;28: 1131–1135. doi:10.1002/pd.2141

611   72.   Pihl K, Larsen T, Laursen I, Krebs L, Christiansen M. First trimester maternal serum pregnancy-specific beta-1-

612   glycoprotein (SP1) as a marker of adverse pregnancy outcome. Prenat Diagn. 2009;29: 1256–1261.

613   doi:10.1002/pd.2408

614   73.   De Villiers CP, Hedley PL, Placing S, Wøjdemann KR, Shalmi A-C, Carlsen AL, et al. Placental protein-13 (PP13) in

615   combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and

616   early preeclampsia. Clin Chem Lab Med. 2017;56: 65–74. doi:10.1515/cclm-2017-0356

617   74.   Thagaard IN, Krebs L, Holm J-C, Lange T, Larsen T, Christiansen M. Adiponectin and leptin as first trimester

618   markers for gestational diabetes mellitus: a cohort study. Clin Chem Lab Med. 2017;55: 1805–1812.

619   doi:10.1515/cclm-2017-0427

620   75.   Hedley PL, Placing S, Wøjdemann K, Carlsen AL, Shalmi A-C, Sundberg K, et al. Free leptin index and PAPP-A: a

621   first trimester maternal serum screening test for pre-eclampsia. Prenat Diagn. 2010;30: 103–109.

622   doi:10.1002/pd.2337

623   76.   Godfrey KM, Barker DJ. Fetal programming and adult health. Public Health Nutr. 2001;4: 611–624.

624   doi:10.1079/phn2001145

625   77.   de Jong J, Garne E, Wender-Ozegowska E, Morgan M, de Jong-van den Berg LTW, Wang H. Insulin analogues in

626   pregnancy and specific congenital anomalies: a literature review. Diabetes Metab Res Rev. 2016;32: 366–375.

627   doi:10.1002/dmrr.2730

628   78.   Given JE, Loane M, Garne E, Addor M-C, Bakker M, Bertaut-Nativel B, et al. Metformin exposure in first

629   trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ.

630   2018;361: k2477. doi:10.1136/bmj.k2477

631   79.   Liu X, Ding G, Yang W, Feng X, Li Y, Liu H, et al. Maternal Body Mass Index and Risk of Congenital Heart Defects

632   in Infants: A Dose-Response Meta-Analysis. BioMed Res Int. 2019;2019: 1315796. doi:10.1155/2019/1315796

633   80.   Berglind D, Willmer M, Näslund E, Tynelius P, Sørensen TIA, Rasmussen F. Differences in gestational weight gain

634   between pregnancies before and after maternal bariatric surgery correlate with differences in birth weight but

635   not with scores on the body mass index in early childhood. Pediatr Obes. 2014;9: 427–434. doi:10.1111/j.2047-

636   6310.2013.00205.x

637   81.   Willmer M, Berglind D, Sørensen TIA, Näslund E, Tynelius P, Rasmussen F. Surgically induced interpregnancy

638   weight loss and prevalence of overweight and obesity in offspring. PloS One. 2013;8: e82247.

639   doi:10.1371/journal.pone.0082247

640   82.   Best KE, Tennant PWG, Bell R, Rankin J. Impact of maternal body mass index on the antenatal detection of

641   congenital anomalies. BJOG Int J Obstet Gynaecol. 2012;119: 1503–1511. doi:10.1111/j.1471-

642   0528.2012.03462.x

643   83.   Herskind AM, Almind Pedersen D, Christensen K. Increased prevalence of congenital heart defects in

644   monozygotic and dizygotic twins. Circulation. 2013;128: 1182–1188. doi:10.1161/CIRCULATIONAHA.113.002453

645   84.   Pober BR. Williams-Beuren syndrome. N Engl J Med. 2010;362: 239–252. doi:10.1056/NEJMra0903074

646   85.   Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet EJHG. 2013;21: 8–13.

647   doi:10.1038/ejhg.2012.115

648   86.   WHO. Obesity and overweight. 2020. Available from: https://www.who.int/news-room/fact-

649   sheets/detail/obesity-and-overweight

650   87.   Centers for Disease Control and Prevention. Prevalence of Obesity and Severe Obesity Among Adults: United

651   States, 2017–2018. 2020. Available from: https://www.cdc.gov/nchs/products/databriefs/db360.htm

652   88.   Poston L, Caleyachetty R, Cnattingius S, Corvalán C, Uauy R, Herring S, et al. Preconceptional and maternal

653   obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2016;4: 1025–1036.

654   doi:10.1016/S2213-8587(16)30217-0

655   89.   Baumfeld Y, Novack L, Wiznitzer A, Sheiner E, Henkin Y, Sherf M, et al. Pre-Conception Dyslipidemia Is

656   Associated with Development of Preeclampsia and Gestational Diabetes Mellitus. PloS One. 2015;10: e0139164.

657   doi:10.1371/journal.pone.0139164

658   90.   Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in

659   later life: systematic review and meta-analysis. BMJ. 2007;335: 974. doi:10.1136/bmj.39335.385301.BE

660   91.   Alonso-Ventura V, Li Y, Pasupuleti V, Roman YM, Hernandez AV, Pérez-López FR. Effects of preeclampsia and

661   eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis.

662   Metabolism. 2020;102: 154012. doi:10.1016/j.metabol.2019.154012

Supporting information

S1 Appendix. PRISMA checklist.

S1 Table. Search protocol. PubMed and Embase: Publications between January 1, 1990 and October 6, 2019.

S2 Table. Newcastle-Ottawa Quality Assessment Scale.

S3 Table. Characteristics of included studies. Studies listed after number of CHD cases: studies with most cases first

etc. Abbreviations: ABDCCS, Atlanta Birth Defect Case-Control Study; BDRFSS, Birth Defects Risk Factor Surveillance

Study; CHDs, congenital heart defects; CM, congenital malformations; CSL, The Consortium of Safe Labor; DM1,

diabetes mellitus type 1; DM2, diabetes mellitus type 2; GDM, gestational diabetes mellitus; NBDPS, National Birth

Defects Prevention Study; NOS, Newcastle Ottawa Scale; PE, preeclampsia; PGDM, pregestational diabetes.

S1 Fig. Maternal metabolic disorders and risk of heterotaxia in the offspring. Obesity is defined as BMI $\geq$ 30 kg/m^2

unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2;

all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined from ICD-

10 codes; £, BMI $\geq$ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; $, Brodwall et al.

pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type

2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio;

RR, risk ratio.

S2 Fig. Maternal metabolic disorders and risk of univentricular heart in the offspring. Obesity is defined as BMI $\geq$ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; £, BMI $\geq$ 35 kg/m^2; †, BMI 35-<40 kg/m^2;

#, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM,

gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk

ratio..

S3 Fig. Maternal metabolic disorders and risk of conotruncal defects in the offspring. Obesity is defined as BMI $\geq$ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined

from ICD-10 codes; £, BMI ≥ 35 kg/m^2. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes

type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence

ratio; RR, risk ratio.

S4 Fig. Maternal metabolic disorders and risk of common truncus in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; #, untreated hypertension.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S5 Fig. Maternal metabolic disorders and risk of transposition of the great arteries in the offspring. Obesity is

defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM

are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects;

£, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-

onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM,

gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk

ratio.

S6 Fig. Maternal metabolic disorders and risk of Tetralogy of Fallot in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; €,

BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe

PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio..

S7 Fig. Maternal metabolic disorders and risk of double outlet right ventricle in the offspring. Obesity is defined as

BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined

as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted. Abbreviations: BMI, body mass

index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia;

PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S8 Fig. Maternal metabolic disorders and risk of aortic arch defects in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; †, BMI 35-<40 kg/m^2. Abbreviations:

BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE,

preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S9 Fig. Maternal metabolic disorders and risk of atrioventricular septal defects in the offspring. Obesity is defined as

BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined

as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity

defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled

early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2;

GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR,

risk ratio.

S10 Fig. Maternal metabolic disorders and risk of total anomalous pulmonary venous return in the offspring.

Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week

34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §,

isolated defects; £, BMI ≥ 35 kg/m^2; Δ, estimates for anomalous pulmonary venous return; #, untreated hypertension.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S11 Fig. Maternal metabolic disorders and risk of left ventricular outflow tract obstruction in the offspring. Obesity

is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34;

PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated

defects; ¤, obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2. Abbreviations: BMI, body mass index; DM1, diabetes

type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational

diabetes; PR, prevalence ratio; RR, risk ratio.

S12 Fig. Maternal metabolic disorders and risk of hypoplastic left heart syndrome in the offspring. Obesity is defined

as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are

defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £,

BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S13 Fig. Maternal metabolic disorders and risk of coarctation of the aorta in the offspring. Obesity is defined as BMI

≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as

DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35

kg/m^2; €, BMI > 29 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S14 Fig. Maternal metabolic disorders and risk of aortic stenosis in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; #,

untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM,

gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk

ratio.

S15 Fig. Maternal metabolic disorders and risk of right ventricular outflow tract obstruction in the offspring. Obesity

is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34;

PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated

defects; £, BMI ≥ 35 kg/m^2; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1;

DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes;

PR, prevalence ratio; RR, risk ratio.

S16 Fig. Maternal metabolic disorders and risk of pulmonary valve stenosis in the offspring. Obesity is defined as

BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined

as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35

kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1;

DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes;

PR, prevalence ratio; RR, risk ratio.

S17 Fig. Maternal metabolic disorders and risk of Ebstein's anomaly in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; #,

untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index;

DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM,

pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S18 Fig. Maternal metabolic disorders and risk of septal defects in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S19 Fig. Maternal metabolic disorders and risk of ventricular septal defects in the offspring. Obesity is defined as

BMI ≥ 30 kg/m2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined

as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity

defined from ICD-10 codes; £, BMI ≥ 35 kg/m2; €, BMI > 29 kg/m2; †, BMI 35-<40 kg/m2; #, untreated hypertension; $,

Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1;

DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes;

PR, prevalence ratio; RR, risk ratio.

S20 Fig. Maternal metabolic disorders and risk of atrial septal defects in the offspring. Obesity is defined as BMI ≥ 30

kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined

from ICD-10 codes; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,

odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.